ERICO: The Efficacy of Full Mouth Erythritol Powder Air-Polishing Therapy (FM-EPAPT) Versus Traditional Ultrasonic Debridment (UD): a Randomized Controlled Study.

Sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Other)
Overall Status
Completed
CT.gov ID
NCT04455269
Collaborator
(none)
41
1
2
22.9
1.8

Study Details

Study Description

Brief Summary

Traditional methods for plaque and calculus removal involve the use of mechanical and/or manual instruments, followed by surface polishing with rubber cups and low abrasive pastes. These instruments may cause the unintended removal of hard dental tissue, such as enamel, cementum and dentine, increasing surface roughness. Moreover, they can lead to gingival recession and consequent hypersensitivity and discomfort during treatment. New minimally-invasive approaches to biofilm removal have been recently introduced with the aim to limit the negative impact on the oral tissue. Air-polishing with low-abrasiveness powders are proven suitable for both for supra- and sub-gingival plaque removal. The use of low-abrasiveness powders could lead to several advantages, such as reduction of treatment discomfort, shorter treatment time, the possibility of cleaning areas with difficult access and minor damage on soft and hard tissues.

Aim: the aim of this study is to evaluate the efficacy of the Full Mouth Erithrytol Powder Air-Polishing Therapy compared to traditional ultrasonic debridment (UD) and polishing in patient affected by gingivitis.

Test hypotesis: there is no difference in clinical outcome between two methods against the hypothesis of a difference in terms of changes in Blending on Probing (BOP).

To test this hypothesis, the patients, upon initial evaluation, were treated in split mouth:
  • The control group undergoing the standard procedure with full-mouth ultrasonic debridement and polishing with rubber cup and abrasive paste.

  • The study group undergoing an innovative procedure involving full-mouth air-polishing followed by ultrasonic calculus removal.

Follow-ups are scheduled at 2 weeks and 1, 3, 6 and 12 months.

Condition or Disease Intervention/Treatment Phase
  • Device: AIRFLOW® with PLUS® powder and PIEZON® scaler
  • Device: PIEZON® scaler and rubber cup with abrasive paste
N/A

Detailed Description

TRIAL DESIGN:

Mono-centric, pragmatic, double-blinded, randomized clinical trial (RCT) with split-mouth design. The trial will have a one year of duration.

PRIMARY OUTCOME:
  • Change in BoP: change in percentage of sites positive to bleeding on probing.
SECONDARY OUTCOMES:
  • Change in Plaque Index (PI): change in percentage of sites with presence of plaque. Baseline values will be compared to the values recorded at follow-up visits.

  • Change in Residual Plaque Area (RPA): Post-treatment percentage of tooth area with residual plaque, visualised via plaque disclosing agent. This will be calculated with computer software analysis (ImageJ) on clinical photographs.

  • Change in Periodontal Attachment Level (PAL): change in mean value for each patient will be calculated. Baseline values will be compared to the values recorded at follow-up visits.

  • Change in (Pocket Probing Depth) PPD: change in mean value for each patient will be calculated. Baseline values will be compared to the values recorded at follow-up visits.

  • Duration of the treatment: calculated in minutes. Time will be recorded starting from the opening the randomisation envelope until the clinician is satisfied with the clinical result.

  • Comfort of the patient: an anonymous questionnaire will be administered at baseline and each recall appointment.

  • Sensation of cleanliness: an anonymous questionnaire will be administered at baseline and each recall appointment.

STUDY POPULATION:

41 Systemically healthy patients affected by gingivitis will be included in this study. Presence of gingivitis is defined as: absence of Probing pocket depth (PPD) > 4mm and presence of BoP >25%.

INCLUSION CRITERIA:
  • Patients affected by gingivitis (BoP >25%);

  • Patients with at least 5 teeth per quadrant;

  • Systemically healthy;

  • Age > 18 years;

  • Smoking less than 10 cigarettes a day.

Study Design

Study Type:
Interventional
Actual Enrollment :
41 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Mono-centric, double-blinded, randomized clinical trial (RCT) with a split-mouth design.Mono-centric, double-blinded, randomized clinical trial (RCT) with a split-mouth design.
Masking:
Single (Investigator)
Masking Description:
Clinical examination, collection of periodontal parameters and clinical photographs were performed by the same trained dentist blinded to the treatment.
Primary Purpose:
Treatment
Official Title:
The Efficacy of Full Mouth Erythritol Powder Air-Polishing Therapy (FM-EPAPT) Versus Traditional Ultrasonic Debridment (UD): a Randomized Controlled Study.
Actual Study Start Date :
May 3, 2017
Actual Primary Completion Date :
Apr 1, 2019
Actual Study Completion Date :
Apr 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Full-Mouth Erythritol Powder Air-polishing Therapy (FM-EPAPT)

The quadrants allocated to FM-EPAPT underwent the following steps: Decontamination of soft tissues with air-polishing and erythritol powder; Supra-gingival removal biofilm with air-polishing and erythritol powder; Sub-gingival removal of biofilm with air-polishing and erythritol; Calculus removal with a piezoceramic scaler.

Device: AIRFLOW® with PLUS® powder and PIEZON® scaler
Air-polishing will be use as main instrument for biofilm and stains removal, followed by ultrasonic scaling

Active Comparator: Ultrasonic debridement and abrasive paste (US+P)

The quadrants allocated to US+P treatment underwent the following steps: Full-mouth ultrasonic debridement with piezoceramic scaler; Plaque removal and polishing with soft rubber cup and low-RDA polishing paste

Device: PIEZON® scaler and rubber cup with abrasive paste
Application of ultrasonic scaler on the entire dentition, followed by residual biofilm and stains removal and polishing

Outcome Measures

Primary Outcome Measures

  1. Change in Bleeding on Probing (BoP) [study completion, an average of 18 months]

    Change in percentage of sites positive to bleeding on probing

Secondary Outcome Measures

  1. Change in Plaque Index (PI) [From baseline to study completion (12 months)]

    Change in percentage of site with plaque. Baseline values will be compared to the values recorded in the follow-up visits.

  2. Change in residual plaque area (RPA) [From baseline to study completion (12 months)]

    Post-treatment residual plaque recorded via plaque disclosing agent, clinical photographs and image software analysis

  3. Change in Periodontal Attachment Level (PAL) [From baseline to study completion (12 months)]

    Change in mean PAL value for each patient should be calculated. Baseline values will be compared to the values recorded in the follow-up visits.

  4. Change in Pocket Probing Depth (PPD) [From baseline to study completion (12 months)]

    Change in mean PPD value for each patient. Baseline values will be compared to the values recorded in the follow-up visits.

  5. Treatment time [From baseline to study completion (12 months)]

    Calculated in minutes, from the opening of the randomisation envelope to the end of the instrumentation.

  6. Comfort of the patient [From baseline to study completion (12 months)]

    An anonymous questionnaire will be administered at baseline and each recall appointment. The score is on a scale: from 0 to 5, where 0 is the minimum discomfort and 5 the maximum discomfort.

  7. Sensation of cleanliness [From baseline to study completion (12 months)]

    An anonymous questionnaire will be administered at baseline and each recall appointment. The score is on a scale of 5 feelings: insufficient, sufficient, average, good and optimal.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Diagnosis of gingivitis (BoP > 25%);

  • Presence of at least 5 teeth per quadrant;

  • Systemically healthy;

  • Age between 20 and 40 years old.

Exclusion Criteria:
  • Presence of periodontal disease, defined as >3 mm of clinical attachment loss at any site;

  • Presence of fixed retainers, orthodontic appliances or complex prothetic restorations;

  • Presence of crowding;

  • Pregnant or lactating;

  • Allergy to chlorhexidine or erythritol;

  • Smoking >10 cigarettes per day;

  • Unwillingness to undergo the proposed treatment and recalls;

Contacts and Locations

Locations

Site City State Country Postal Code
1 Magda Mensi Brescia Lombardia Italy 25123

Sponsors and Collaborators

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Investigators

  • Principal Investigator: Magda Mensi, ASST Spedali Civili di Brescia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Magda Mensi, principal investigator, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
ClinicalTrials.gov Identifier:
NCT04455269
Other Study ID Numbers:
  • ERICO np: 2637
First Posted:
Jul 2, 2020
Last Update Posted:
Jul 15, 2020
Last Verified:
Jul 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Magda Mensi, principal investigator, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 15, 2020